Increasing evidence is available for the use of percutaneous coronary intervention (PCI) in selected patients with unprotected left main (LM) bifurcation coronary lesions. However, little data have been reported on recurrent in-stent restenosis (ISR) for LM bifurcation lesions. The aim of this study was to evaluate the efficacy of a drug-eluting balloon (DEB) for LM bifurcation ISR compared with that of a drug-eluting stent (DES).
C oronary artery bypass graft (CABG) surgery has been considered the standard therapy for the treatment of unprotected left main (LM) coronary artery disease. 1) There is increasing supportive evidence for the use of percutaneous coronary intervention (PCI) in selected patients with unprotected LM lesions and low-tomoderate synergy between PCI with taxus and cardiac surgery (SYNTAX) score due to the improvements of the new stent technology and adjunctive pharmacotherapies. [2] [3] [4] However, there is still no consensus regarding the optimal PCI strategy for unprotected LM stenosis with the use of drug-eluting stents (DES), although more reports have discussed the safety and feasibility of coronary stenting in unprotected LM coronary artery disease in clinical practice. 5) In-stent restenosis (ISR) has been an important issue following PCI, and the rates of recurrent restenosis (approximately 6-6.3%) are extremely high following conventional treatments for ISR lesions. 6) However, little data are available on the treatment of ISR in this area. 7, 8) Drug-eluting balloons (DEBs) have emerged as a potential alternative to the current treatment of ISR. 9) Paclitaxel has been identified as the primary drug for use in DEBs because of its rapid uptake and prolonged retention. 10) Compared to DESs, DEBs provide advantages such as immediate release of drug to the arterial wall, the absence of polymers and stent struts, and cost-effectiveness. In some clinical randomized trials, DEBs have been found to be superior to uncoated balloon angioplasty in the treatment of ISR not only in bare-metal stents (BMSs) 11) but also in DESs. 12, 13) In real-world practice, the feasibility of using DEB for BMS-ISR and DES-ISR was also reported. 14) To the best of our knowledge, there is no clinical result comparing the use of DESs and DEBs in unprotected LM bifurcation ISR coronary artery disease. In addition, physicians have preferred stenting for LM bifurcation recurrent ISR due to the importance of the anatomical site. However, "stent in stent" treatment causes luminal loss, and repeat stenting triggers chronic inflammation and hypersensitivity reactions that might contribute to increased risks of late stent thrombosis and late restenosis. 15, 16) On the other hand, repeat stenting may lead to uneven distribution of drug release, sub-optimal stent ge-Lee, ET AL ometry, and insufficient stent expansion. 15, 16) For these reasons, the DEB is a good alternative; however, we need to know the clinical results regarding DEB for LM bifurcation ISR.
The aim of this study was to compare the differences in clinical outcomes between the use of DES and the use of DEB after unprotected LM bifurcation coronary artery disease ISR.
Methods
The study was approved by the Institutional Review Committee on Human Research of Chang Gung Memorial Hospital for retrospective analysis in consecutive patients with angiographic evidence of unprotected LM bifurcation ISR who refused CABG and underwent PCI between December 2011 and December 2015 in our hospital. Patients and groups: Between December 2011 and December 2015, 104 patients who refused CABG and underwent PCI for unprotected LM bifurcation ISR were retrospectively enrolled. Unprotected LM bifurcation lesions were divided into 2 groups: (1) PCI with further DEB and (2) PCI with further DES. Most of the patients with !2 segments affected Medina LM bifurcation ISR such as (1,1,1), (1,1,0), (1,0,1), and (0,1,1) were treated with further DES implantation. The final treatment with DEB or DES was made by operator's preferences. Clinical outcomes such as target lesion revascularization (TLR), recurrent myocardial infarction (MI), stroke, cardiovascular mortality, and all-cause mortality were analyzed. Cardiovascular mortality and all-cause mortality were compared between the 2 groups. We also separated the patients with DES-ISR specifically and compared clinical outcomes between the 2 groups. Definitions: Unprotected LM bifurcation disease was defined as a stenosis of at least 50% that involved the ostium, body, or distal segment of the LM coronary artery or was within the proximal 5 mm of the left anterior descending artery (LAD) or left circumflex coronary artery (LCX) ostium. TLR is defined as a repeat PCI or CABG for an arterial lesion in the previously treated segment or in an adjacent 5 mm segment. Major adverse cardiac cerebral events (MACCEs) include TLR, MI, stroke, and cardiovascular mortality. Cardiovascular mortality was defined as death related to cardiac arrhythmia. All-cause mortality was defined as death from any cause. Study endpoints: The primary endpoint was a MACCE during the follow-up period. The secondary endpoint was death due to any cause during the follow-up period. Statistical analysis: Data are expressed as a mean ± standard deviation for continuous variables or as counts and percentages for categorical variables. Continuous variables were compared using an independent sample t test or Mann-Whitney U tests. Categorical variables were compared using a chi-square statistic. A Kaplan-Meier curve was performed for one-year TLR and one-year cardiovascular mortality in the DEB and DES groups. All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY). A P value < 0.05 was considered to be statistically significant. Table I shows the patient characteristics of both groups. Most of the patients from both groups who underwent PCI had acute coronary syndrome (82.7% in DEB group versus 72.4% in DES group, P = 0.280). The risk factors between the 2 groups were the same without statistical differences except for a lower percentage of previous stroke in the DEB group than in the DES group (5.3% versus 24.1%, P = 0.01). The creatinine levels of both groups were similar (1.45 ± 0.52 mg/dL versus 1.46 ± 0.85 mg/dL, P = 0.975). The Syntax scores between the groups were also similar (19.84 ± 11.39 versus 23.38 ± 10.76, P = 0.152). The EuroSCOREs between the groups were also similar (4.55 ± 2.63 versus 3.97 ± 2.61, P = 0.315). The previous DES distribution was 65.3% in the DEB group and 44.8% in the DES group, without statistical differences. A relatively high one-year follow-up rate was observed in both groups (52.0 versus 44.8%; P = 0.662). Lesion characteristics: Table II demonstrates the lesion characteristics of both groups. The most frequently found Medina classification was (0,0,1) in the DEB group and (1,1,1) (0,1,0) in the DES group with statistically significant difference. Lesion types were similar between the 2 groups, and the majority was focal lesion (63.2 versus 60.0%; 0.837). Pre-PCI average stenosis and diameter were similar in both groups but greater post-PCI minimal luminal diameter (3.11 ± 0.47 versus 2.64 ± 0.57 mm, P < 0.001) and reference luminal diameter (3.64 ± 0.58 versus 3.25 ± 0.62 mm, P = 0.002) were found in the DES group. The most-used stenting technique for LM bifurcation ISR was the one-stent strategy (72.4%). The use of intravascular ultrasound was similar in both groups (49.3 versus 41.4%; P = 0.516). The use of intra-aortic balloon pumping was similar between the 2 groups (8.0 versus 10.3%; P = 0.707). The implanted device diameter was significantly larger in the DES group compared with the DEB group (3.49 ± 0.35 versus 3.19 ± 0.34 mm, P < 0.001). Table III provides the one-year clinical outcomes comparing DEB and DES in MACCE, including TLR, recurrent MI, stroke, and cardiovascular mortality. Table III also shows the one-year clinical outcomes in all-cause mortality between the groups. The MACCE rates were similar in the DEB and DES groups (20.3 versus 24.0%, P = 0.777), but cardiovascular mortality rate was significantly higher in the DES group (10.7 versus 0%, P = 0.02). The all-cause mortality rate was higher in the DES group, but without statistical significance (21.4 versus 6.8%, P = 0.067). The Kaplan-Meier curves of one-year clinical outcomes of DEB and DES groups in target lesion revascularization and cardiovascular mortality: The Figure shows the Kaplan-Meier curves of one-year clinical outcomes of the DEB and DES groups. There was no statistically significant difference in TLR (P = 0.561) between the 2 groups, but significant difference in cardiovascular mortality (P = 0.048) between the 2 groups. specifically DES-ISR: Table IV demonstrates the oneyear clinical outcomes, comparing DEB and DES groups in MACCE and all-cause mortality, specifically in the DES-ISR sub-group. Again, the MACCE rate was lower in the DEB group than in the DES group (18.4 versus 30.8%, P = 0.328) without a statistically significant difference, but a significantly higher cardiovascular mortality rate was found in the DES group compared with the DEB group (15.4 versus 0%, P = 0.006). The all-cause mortality rate was higher in the DES group but without statistical significance (23.1 versus 8.2%, P = 0.139).
Results
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Discussion
CABG surgery has been considered the standard therapy for the treatment of unprotected LM coronary artery disease.
1) However, after the improvement of PCI technique and stent structure, increasing evidence was available for the use of PCI in selected patients with unprotected LM bifurcation coronary lesions with low to moderate SYNTAX score. [17] [18] [19] [20] Aside from the use of DES 18) and IVUS, 21, 22) there is no consensus regarding the optimal PCI strategy for unprotected LM bifurcation stenosis. Tagagi et al. published the MITO registry which proved the strategy of DES use is better than balloon angioplasty, and repeat PCI has a higher restenosis rate. 23, 24) Ojeda et al. also published the CORPAL registry which concluded that simple approach has a lower incidence of MACE than complex approach in unprotected LM ISR with 4 years MACE 22%.
25) The data of long-term followup after unprotected LM ISR PCI was rare. A small single-center experience also had the high incidence of MACE up to 28.5% at three-year follow-up. 26) In our study, the patient group had already declined the CABG before and also at the index procedure. The EuroSCORE was also higher with 3.97 ± 2.61 in DES group and 4.55 ± 2.63 in DEB group which was relatively higher than the average of MITO registry (3.62 ± 2.86). 24) Patients in both of our groups had extremely high incidence of hemodialysis (33.3% and 20.7%) and heart failure (34.7% and 31.0%), which were relatively higher than the average of MITO registry (4.8% in severe chronic kidney disease). 24) LM bifurcation is an important anatomical site, and serious events arise from main trunk occlusion following PCI. Repeat stenting causes luminal loss and triggers chronic inflammation and hypersensitivity reactions, uneven distribution of drug release, sub-optimal stent geometry, and insufficient stent expansion. 15, 16) All these problems may increase the risks of stent thrombosis and restenosis. The CORPAL registry once told us the impor-Lee, ET AL Data are expressed as mean ± SD or as number (percentage). n indicates number; L, lesion; DEB, drug-eluting balloon; DES, drug-eluting stent; PCI, percutaneous coronary intervention; MLD, minimal luminal diameter; RLD, reference luminal diameter; and IABP, intra-aortic balloon pump. tance of simple strategy in unprotected LM ISR. 25) Simple strategy for unprotected LM ISR was also associated with lower risk of long-term MACE regardless of the restenosis extent. 25, 27) In our study, DES treatment group was used mainly in !2 segments affected Medina LM bifurcation ISR such as (1,1,1), (1,1,0), (1,0,1) , and (0,1,1) (51.6% versus 38.7%) than DEB treatment group. On the other hand, repeat stenting may not be the perfect strategy for LM bifurcation ISR.
DEBs have emerged as a potential alternative to the current treatment of ISR, and provide the freedom of polymers and stent struts. Therefore, DEBs prevent the problem of "stent in stent," do not cause stent thrombosis, and may decrease the possibility of sudden death if acute stent thrombosis occurs after repeat stenting. The previous registry showed that the use of DEB in patients with bifurcation lesions was effective and safe up to 4 months following PCI in patients with coronary artery bifurcation lesions. 28) However, no randomized study discussed the use of DEBs for LM bifurcation ISR, and one observational study reported that coronary ostial lesion was closely associated with recurrent TLR after DEB use. 29) In our study, the use of DEB in unprotected LM ISR PCI not only had the lower incidence of cardiac mortality than the use of DES (0% versus 10.7%, P = 0.02) but also had the lower incidence of all-cause mortality (6.8% versus 21.4%, P = 0.067) and MACCE (20.3% versus 24.0%, P = 0.777) in one-year follow-up. This may hint the operator that less stent strut may benefit the patient in less stent thrombosis occurring after PCI to LM-ISR. Figure. A: The Kaplan-Meier curves of one-year clinical outcomes of the DEB and DES groups presented no statistically significant difference in target lesion revascularization (P = 0.561) between the 2 groups. B: The KaplanMeier curves of one-year clinical outcomes of the DEB and DES groups presented significant difference in cardiovascular mortality (P = 0.048) between the 2 groups. In this study, most patients presented with acute coronary syndrome and with a high prevalence of comorbidities including diabetes mellitus, hypertension, and renal disease. Most patients in both groups had multiple vessel coronary artery disease. Higher SYNTAX score was noted in the DES group, but no significant difference presented. The most frequently found Medina classification was (1,1,1) and (0,1,0) in the DES group. These findings were compatible with clinical practice, with physicians wanting to implant the DES in the patients with higher SYNTAX score and (1,1,1) Medina classification. The most prevalent type of ISR lesion was focal lesion in both groups. Lee et al. stated the incidence of ISR was 17.7% after DES stenting for LM lesion, and most angiographic ISR in LM lesions were focal-type (80.3%). 7) Although the post-PCI angiographic results including higher stenotic percentage and smaller minimal luminal diameter were worse in the DEB group, the rates of TLR were similar between the 2 groups. A higher incidence of oneyear recurrent MI (6.0 versus 12.5%; P = 0.375) and oneyear cardiovascular death (0 versus 10.7%; P = 0.020) were found in the DES group. In this study, the technique that was often used for DES implantation for LM bifurcation ISR was the one-stent strategy. Moreover, if we focused on the patients with DES-ISR, the rate of TLR became higher in the DES group even with no significant difference. This phenomenon may hint that the "stent in stent" strategy is not suitable for DES-ISR in the LM bifurcation site due to luminal loss and a high probability of restenosis. In this study, the reasons for cardiovascular death were ventricular arrhythmia and sudden collapse, and may be related to possible stent thrombosis. Importantly, there were no cardiovascular deaths in the DEB group, because DEB did not cause stent thrombosis due to no repeated endothelializations and no additional stent struts. Therefore, DEB is a feasible strategy for LM bifurcation ISR. Limitations: Our study had some limitations, including that it was non-randomized and had a small number of patients. Although this study is non-randomized, the baseline characteristics were similar between the 2 groups. In addition, no previous study showed the comparison of clinical outcomes between DEB and DES use for LM bifurcation ISR. Our study provided much-needed experience with DEB for LM bifurcation ISR.
CLINICAL OUTCOMES AFTER DEB OR DES USE FOR LM ISR
Conclusion
It is feasible to use DEB for LM bifurcation ISR. When comparing the technique with DES, a similar TLR rate, lower recurrent MI, and lower cardiovascular death were noted after DEB treatment.
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